AstraZeneca Korea announced that type 2 diabetes treatment 'Forxiga' will be subject to health insurance benefit
As Sodium-glucose co transporter 2 (SGLT-2) Inhibitors series diabetes treatment was subject to health insurance benefits, all stages of diabetes patients in domestic were able to get a new treatment option.
AstraZeneca Korea announced that type 2 diabetes treatment 'Forxiga (ingredient : dapagl...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
